Pulmonary function in people living with human immunodeficiency virus: a meta-analysis
Díez-Manglano, Jesús (Universidad de Zaragoza) ; Corral-Beamonte, Esther del
Resumen: Background: HIV can infect bronchial epithelial cells rendering individuals susceptible to lung damage. Our objective was to determine the effects of human immunodeficiency virus (HIV) infection on pulmonary function tests.
Methods:We performed a meta-analysis after conducting a literature search in PubMed, Embase, Cochrane Library and Virtual Health Library databases from inception to December 31st, 2022. We employed the inverse variance method with a random effects model to calculate the effect estimate as the mean difference (MD) and 95% confidence interval (CI). We calculated the heterogeneity with the I2 statistic and performed a meta-regression analysis by age, sex, smoking, CD4 T-cells count and antiretroviral therapy. We also conducted a sensitivity analysis according to the studies’ publication date, and excluding the study with the greatest weight in the effect. The PROSPERO registry number was CRD42023401105.
Results: The meta-analysis included 20 studies, with 7621 living with HIV and 7410 control participants. The pooled MD (95%CI) for the predicted percentage of FEV1, FVC and DLCO were −3.12 (−5.17, −1.06); p = 0.003, −1.51 (−3.04, 0.02); p = 0.05, and −5.26 (−6.64, −3.87); p < 0.001, respectively. The pooled MD for FEV1/FVC was −0.01 (−0.02, −0.01); p = 0.002. In all cases, there was a considerable heterogeneity. The meta-regression analysis showed that among studies heterogeneity was not explained by patient age, smoking, CD4 T-cells count or antiretroviral therapy.
Conclusion: Pulmonary function tests are impaired in people living with HIV, independently of age, smoking, CD4 T-cells count, and geographical region.
Idioma: Inglés
DOI: 10.1016/j.arbres.2024.01.009
Año: 2024
Publicado en: Archivos de Bronconeumologia 60, 4 (2024), 462-470
ISSN: 0300-2896
Factor impacto JCR: 9.2 (2024)
Categ. JCR: RESPIRATORY SYSTEM rank: 6 / 108 = 0.056 (2024) - Q1 - T1
Factor impacto CITESCORE: 3.5 - Pulmonary and Respiratory Medicine (Q3)
Factor impacto SCIMAGO: 0.466 - Pulmonary and Respiratory Medicine (Q3)
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Derechos reservados por el editor de la revista
Exportado de SIDERAL (2026-01-12-12:47:52)
Visitas y descargas
Methods:We performed a meta-analysis after conducting a literature search in PubMed, Embase, Cochrane Library and Virtual Health Library databases from inception to December 31st, 2022. We employed the inverse variance method with a random effects model to calculate the effect estimate as the mean difference (MD) and 95% confidence interval (CI). We calculated the heterogeneity with the I2 statistic and performed a meta-regression analysis by age, sex, smoking, CD4 T-cells count and antiretroviral therapy. We also conducted a sensitivity analysis according to the studies’ publication date, and excluding the study with the greatest weight in the effect. The PROSPERO registry number was CRD42023401105.
Results: The meta-analysis included 20 studies, with 7621 living with HIV and 7410 control participants. The pooled MD (95%CI) for the predicted percentage of FEV1, FVC and DLCO were −3.12 (−5.17, −1.06); p = 0.003, −1.51 (−3.04, 0.02); p = 0.05, and −5.26 (−6.64, −3.87); p < 0.001, respectively. The pooled MD for FEV1/FVC was −0.01 (−0.02, −0.01); p = 0.002. In all cases, there was a considerable heterogeneity. The meta-regression analysis showed that among studies heterogeneity was not explained by patient age, smoking, CD4 T-cells count or antiretroviral therapy.
Conclusion: Pulmonary function tests are impaired in people living with HIV, independently of age, smoking, CD4 T-cells count, and geographical region.
Idioma: Inglés
DOI: 10.1016/j.arbres.2024.01.009
Año: 2024
Publicado en: Archivos de Bronconeumologia 60, 4 (2024), 462-470
ISSN: 0300-2896
Factor impacto JCR: 9.2 (2024)
Categ. JCR: RESPIRATORY SYSTEM rank: 6 / 108 = 0.056 (2024) - Q1 - T1
Factor impacto CITESCORE: 3.5 - Pulmonary and Respiratory Medicine (Q3)
Factor impacto SCIMAGO: 0.466 - Pulmonary and Respiratory Medicine (Q3)
Tipo y forma: Artículo (PostPrint)
Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)
Derechos reservados por el editor de la revistaExportado de SIDERAL (2026-01-12-12:47:52)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Medicina
Registro creado el 2024-02-09, última modificación el 2026-01-12